Interestingly, CTLA-4 blockade loses efficacy in CD4+ T cell-depleted mice, suggesting its anti-tumor effects rely on CD4+ T cell-mediated modulation of dendritic cells and microglia, offering new insights into its role in GBM treatment (46). The gene discussed is CD4; the disease is glioblastoma.